TABLE 1.

In vitro activities of cefepime-zidebactam and comparators tested against 719 isolates of E. coli and 33 isolates of carbapenem-resistant E. coli collected in China, 2018^a

Antimicrobial agent	E. coli (n = 719)					Carbapenem-resistant E. coli (n = 33)
	MIC (mg/liter)			R, %	S, %	MIC (mg/liter)			R, %	S, %
	Range	50%	90%			Range	50%	90%
Cefepime-zidebactam	≤0.03 to 32	0.06	0.125	0.4	99	0.06 to 32	0.125	8	9.1	81.8
Ceftazidime-avibactam	≤0.03 to >64	0.125	0.5	4.5	95.5	0.25 to >64	>64	>64	90.9	9.1
Ceftolozane-tazobactam	≤0.06 to >128	0.25	4	9	89.6	4 to >128	>128	>128	97	0
Cefepime-tazobactam	≤0.03 to >64	0.06	0.5	4.3	94.7	8 to >64	>64	>64	90.9	0
Piperacillin-tazobactam	≤2 to >256	≤2	32	10.6	86.4	128 to >256	>256	>256	100	0
Cefoperazone-sulbactam	≤1 to >128	8	64	10.4	75.2	32 to >128	>128	>128	97	0
Cefazolin	1 to >32	>32	>32	71.9	15.4	>32 to >32	>32	>32	100	0
Cefuroxime	≤0.5 to >32	>32	>32	62.4	33.7	>32 to >32	>32	>32	100	0
Ceftriaxone	0.5 to >32	>32	>32	61.3	38.2	>32 to >32	>32	>32	100	0
Ceftazidime	≤0.25 to >32	2	>32	26.8	63.3	8 to >32	>32	>32	97	0
Cefepime	≤0.06 to >128	4	128	33.2	45.1	16 to >128	>128	>128	100	0
Moxalactam	≤0.06 to >128	0.5	16	63.1	36.5	8 to >128	>128	>128	100	0
Aztreonam	≤1 to >128	8	64	41.4	47.6	≤1 to >128	64	>128	75.8	21.2
Imipenem	≤0.06 to >128	0.125	0.5	4.3	94.9	2 to >128	16	64	93.9	0
Meropenem	≤0.03 to >64	≤0.03	≤0.03	4.2	95.3	2 to >64	16	64	90.9	0
Amikacin	≤1 to >128	2	8	5.1	88.3	≤1 to >128	4	>128	30.3	57.6
Ciprofloxacin	≤0.06 to >8	>8	>8	64.3	26.4	0.25 to >8	>8	>8	93.9	6.1
Levofloxacin	≤0.125 to >16	8	32	60.2	33.5	0.5 to >16	16	32	90.9	6.1
Trimethoprim-sulfamethoxazole	≤0.25 to >32	>32	>32	64.8	35.2	≤0.25 to >32	>32	>32	84.8	15.2
Polymyxin B	≤0.125 to >16	0.5	1	0.8	98.5	0.25 to >16	0.5	16	12.1	87.9
Tigecycline	≤0.06 to 4	0.125	0.25	0	99.7	0.125 to 4	0.25	1	0	97

^aR, resistant; S, susceptible.